Tyler Zeronda
Director of Finance/CFO en VYNE THERAPEUTICS INC. .
Fortuna: 404 451 $ al 31/03/2024
Perfil
Tyler Zeronda is currently the Chief Financial Officer & Treasurer at VYNE Therapeutics, Inc. He previously worked as the Director-Finance at Aerie Pharmaceuticals, Inc. Mr. Zeronda holds a graduate degree from the University of Virginia and an undergraduate degree from Lafayette College.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VYNE THERAPEUTICS INC
0.93% | 01/04/2024 | 131 743 ( 0.93% ) | 404 451 $ | 31/03/2024 |
Cargos activos de Tyler Zeronda
| Empresas | Cargo | Inicio |
|---|---|---|
| VYNE THERAPEUTICS INC. | Director of Finance/CFO | 18/06/2021 |
Antiguos cargos conocidos de Tyler Zeronda.
| Empresas | Cargo | Fin |
|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Director of Finance/CFO | - |
Formación de Tyler Zeronda.
| University of Virginia | Graduate Degree |
| Lafayette College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| VYNE THERAPEUTICS INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
- Bolsa de valores
- Insiders
- Tyler Zeronda
